{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:16:59Z","timestamp":1788322619746,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["965193"],"award-info":[{"award-number":["965193"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijgc.2026.104959","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T22:23:48Z","timestamp":1786227828000},"page":"104959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biological features associated with poor response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4331-5419","authenticated-orcid":false,"given":"Anna","family":"Rajavuori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7329-8934","authenticated-orcid":false,"given":"Veli-Matti","family":"Isoviita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9596-2832","authenticated-orcid":false,"given":"Daria","family":"Afenteva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3943-1855","authenticated-orcid":false,"given":"Jaakko","family":"Astr\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda","family":"Aakula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai T.N.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5414-3726","authenticated-orcid":false,"given":"Mara","family":"Santarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9541-8177","authenticated-orcid":false,"given":"Giulia","family":"Micoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5895-1808","authenticated-orcid":false,"given":"Taru A.","family":"Muranen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titta","family":"Joutsiniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5127-5619","authenticated-orcid":false,"given":"Benno","family":"Schwikoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7467-8434","authenticated-orcid":false,"given":"Anni","family":"Virtanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7749-2694","authenticated-orcid":false,"given":"Sampsa","family":"Hautaniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1063-2736","authenticated-orcid":false,"given":"Jaana","family":"Oikkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0854-7225","authenticated-orcid":false,"given":"Johanna","family":"Hynninen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ijgc.2026.104959_bib1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"9990","key":"10.1016\/j.ijgc.2026.104959_bib2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104959_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.39893","article-title":"Utilization of primary cytoreductive surgery for advanced-stage ovarian cancer","volume":"7","author":"Bercow","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104959_bib4","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1158\/1078-0432.CCR-08-1564","article-title":"Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas","volume":"15","author":"Etemadmoghadam","year":"2009","journal-title":"Clin Cancer Res."},{"issue":"1","key":"10.1016\/j.ijgc.2026.104959_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2016.05.022","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline","volume":"143","author":"Wright","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104959_bib6","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.3802\/jgo.2020.31.e17","article-title":"Characteristics and survival of patients with ovarian cancer treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery","volume":"31","author":"Liu","year":"2020","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104959_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1387281","article-title":"Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group","volume":"14","author":"Stiegeler","year":"2024","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104959_bib8","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1158\/2159-8290.CD-25-0652","article-title":"Decoding the genomic and functional landscape of emerging subtypes in ovarian cancer","volume":"15","author":"Micoli","year":"2025","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.ijgc.2026.104959_bib9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","article-title":"PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104959_bib10","article-title":"Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer","volume":"6","author":"Afenteva","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ijgc.2026.104959_bib11","unstructured":"Integration of multiple data levels to improve diagnosis, predict treatment response and suggest targets to overcome therapy resistance in high-grade serous ovarian cancer. ClinicalTrials.gov. Accessed 11 November 2025. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04846933."},{"issue":"2","key":"10.1016\/j.ijgc.2026.104959_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104959_bib13","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.3390\/cancers12123730","article-title":"CA125 and ovarian cancer: a comprehensive review","volume":"12","author":"Charkhchi","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104959_bib14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PGP.0000000000000513","article-title":"Assessment of a Chemotherapy Response Score (CRS) system for tubo-ovarian High-Grade Serous Carcinoma (HGSC)","volume":"38","author":"Ditzel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ijgc.2026.104959_bib15","first-page":"347","article-title":"Marching cubes: a high resolution 3D surface construction algorithm","volume":"1","author":"Lorensen","year":"1998"},{"issue":"19","key":"10.1016\/j.ijgc.2026.104959_bib16","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1093\/bioinformatics\/btz133","article-title":"Anduril 2: Upgraded large-scale data integration framework","volume":"35","author":"Cervera","year":"2019","journal-title":"Bioinformatics"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104959_bib17","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.ccell.2023.04.017","article-title":"Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma","volume":"41","author":"Lahtinen","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijgc.2026.104959_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115630","article-title":"Circulating tumor DNA-based copy-number profiles enable monitoring treatment effects during therapy in high-grade serous carcinoma","volume":"168","author":"Nguyen","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104959_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41698-022-00339-8","article-title":"Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer","volume":"6","author":"Perez-Villatoro","year":"2022","journal-title":"npj Precis Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104959_bib20","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1038\/s41467-023-39867-7","article-title":"The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma","volume":"14","author":"Smith","year":"2023","journal-title":"Nat Commun"},{"issue":"7793","key":"10.1016\/j.ijgc.2026.104959_bib21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41586-019-1907-7","article-title":"The evolutionary history of 2,658 cancers","volume":"578","author":"Gerstung","year":"2020","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.ijgc.2026.104959_bib22","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/bioinformatics\/btab178","article-title":"PRISM: recovering cell-type-specific expression profiles from individual composite RNA-seq samples","volume":"37","author":"H\u00e4kkinen","year":"2021","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104959_bib23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/157489307780618231","article-title":"Gene set enrichment analysis (GSEA) for interpreting gene expression profiles","volume":"2","author":"Shi","year":"2007","journal-title":"Curr Bioinform"},{"issue":"20","key":"10.1016\/j.ijgc.2026.104959_bib24","doi-asserted-by":"crossref","first-page":"10934","DOI":"10.1093\/nar\/gkad841","article-title":"Expanding the coverage of regulons from high-confidence prior knowledge for accurate estimation of transcription factor activities","volume":"51","author":"M\u00fcller-Dott","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104959_bib25","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 ELIMination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial","volume":"26","author":"You","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104959_bib26","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41571-023-00819-1","article-title":"Heterogeneity and treatment landscape of ovarian carcinoma","volume":"20","author":"Veneziani","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104959_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2025.01.012","article-title":"Chemotherapy Response Score (CRS): a comprehensive review of its prognostic and predictive value in High-Grade Serous Carcinoma (HGSC)","volume":"194","author":"Zannoni","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"7353","key":"10.1016\/j.ijgc.2026.104959_bib28","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.ijgc.2026.104959_bib30","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2217\/bmm-2021-0144","article-title":"Hoxa9-methylated DNA as a diagnostic biomarker of ovarian malignancy","volume":"15","author":"Faaborg","year":"2021","journal-title":"Biomark Med"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104959_bib31","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/cancers11060837","article-title":"Direct and indirect targeting of HOXA9 transcription factor in acute myeloid leukemia","volume":"11","author":"Lambert","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijgc.2026.104959_bib32","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fonc.2018.00322","article-title":"Plasticity of Type I interferon-mediated responses in cancer therapy: from anti-tumor immunity to resistance","volume":"8","author":"Budhwani","year":"2018","journal-title":"Front Oncol"},{"issue":"22","key":"10.1016\/j.ijgc.2026.104959_bib33","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/onc.2010.623","article-title":"Regulation of transcription of hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) by heat shock factors HSF2 and HSF4","volume":"30","author":"Chen","year":"2011","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104959_bib34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/07357900802146204","article-title":"Low expression of Foxo3a is associated with poor prognosis in patients with ovarian cancer","volume":"27","author":"Fei","year":"2009","journal-title":"Cancer Investig"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104959_bib35","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/cancers11050668","article-title":"Review: targeting the transforming growth factor-beta pathway in ovarian cancer","volume":"11","author":"Roane","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104959_bib29","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, Fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"12","key":"10.1016\/j.ijgc.2026.104959_bib36","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/iub.1692","article-title":"High HSF4 expression is an independent indicator of poor overall survival and recurrence free survival in patients with primary colorectal cancer","volume":"69","author":"Yang","year":"2017","journal-title":"IUBMB Life"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104959_bib37","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s00259-018-3961-z","article-title":"18F-FDG-PET\/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer","volume":"45","author":"Vallius","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:39:52Z","timestamp":1788320392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26004901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"alternative-id":["S1048891X26004901"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104959","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological features associated with poor response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104959","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104959"}}